Investigators in the Division of Gynecologic Oncology at Penn Medicine are conducting a clinical trial to investigate combination therapy with olaparib and AZD6738 in women with high grade serous ovarian cancer (including germline or somatic BRCA mutations), or primary peritoneal and/or fallopian tube cancer. [ClinicalTrials.gov Identifier: NCT03462342].
Known as CAPRI, this trial is currently enrolling at Penn Medicine.1
CAPRI is a clinical trial that was developed by using a preclinical drug development platform developed by the Simpkins Lab in the Ovarian Cancer Research Center (OCRC) within the Division of Gynecology Oncology. The goal of this platform is to identify new drug combinations with strong scientific rationale in the laboratory, with the ultimate goal of moving these regimens to the clinic for patients with ovarian cancer.
1. Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI) [ClinicalTrials.gov Identifier: NCT03462342]
